{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:53Z","timestamp":1791397313219,"version":"4.3.3"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ymgme.2021.12.004","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T12:10:39Z","timestamp":1639743039000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression"],"prefix":"10.1016","volume":"135","author":[{"given":"S.J.","family":"van der Veen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"K\u00f6rver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Brands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.P.","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Langeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.12.004_bb0005","series-title":"\u03b1-Galactosidase A Deficiency: Fabry Disease. The Online Metabolic and Molecular Bases of Inherited Disease","author":"Desnick","year":"2014"},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2021.12.004_bb0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2021.12.004_bb0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"12","key":"10.1016\/j.ymgme.2021.12.004_bb0030","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.ymgme.2021.12.004_bb0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) controversies conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"issue":"21","key":"10.1016\/j.ymgme.2021.12.004_bb0040","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ymgme.2021.12.004_bb0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2021.12.004_bb0055","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2019.03.010","article-title":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: a 5-year randomized controlled trial","volume":"127","author":"Ramaswami","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc.Nephrol."},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0070","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.ymgme.2021.12.004_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ymgme.2021.12.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ymgme.2021.12.004_bb0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2021.12.004_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2021.12.004_bb0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","article-title":"Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry registry","volume":"119","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2021.12.004_bb0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2021.12.004_bb0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2021.12.004_bb0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.ymgme.2021.12.004_bb0115","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2021.12.004_bb0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ymgme.2021.12.004_bb0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.12.004_bb0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0135","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2021.12.004_bb0140","first-page":"109","article-title":"Severe infusion reactions to Fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ymgme.2021.12.004_bb0150","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgme.2021.12.004_bb0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1532-429X-15-35","article-title":"Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing","volume":"15","author":"Schulz-Menger","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"2","key":"10.1016\/j.ymgme.2021.12.004_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am. J. Roentgenol."},{"issue":"7","key":"10.1016\/j.ymgme.2021.12.004_bb0165","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp-2019-322268","article-title":"Determinants of cerebral radiological progression in fabry disease","volume":"91","author":"Korver","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ackd.2017.10.002","article-title":"Alternatives for the bedside schwartz equation to estimate glomerular filtration rate in children","volume":"25","author":"Pottel","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0175","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/gfv454","article-title":"An estimated glomerular filtration rate equation for the full age spectrum","volume":"31","author":"Pottel","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ymgme.2021.12.004_bb0180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1373\/clinchem.2012.184259","article-title":"The kidney disease improving global outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution","volume":"59","author":"Lamb","year":"2013","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2021.12.004_bb0185","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1681\/ASN.V24832","article-title":"Is there a \"point of no return\" in progressive renal disease?","volume":"2","author":"Maschio","year":"1991","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2021.12.004_bb0190","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.ymgme.2021.12.004_bb0195","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view","volume":"10","author":"Lambers Heerspink","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","article-title":"Glomerular hyperfiltration: an early marker of nephropathy in Fabry disease","volume":"141","author":"Riccio","year":"2019","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/1479164118776465","article-title":"Long-term prospective observation suggests that glomerular hyperfiltration is associated with rapid decline in renal filtration function: a multiethnic study","volume":"15","author":"Low","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.ymgme.2021.12.004_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","article-title":"Normal values for cardiovascular magnetic resonance in adults and children","volume":"17","author":"Kawel-Boehm","year":"2015","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"6","key":"10.1016\/j.ymgme.2021.12.004_bb0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1067\/mje.2001.113258","article-title":"Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study","volume":"14","author":"Ilercil","year":"2001","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12968-017-0327-9","article-title":"Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort","volume":"19","author":"Petersen","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"22","key":"10.1016\/j.ymgme.2021.12.004_bb0225","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2021.12.004_bb0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1148\/radiol.2019191385","article-title":"Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease","volume":"294","author":"Hanneman","year":"2020","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.ymgme.2021.12.004_bb0235","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"19","key":"10.1016\/j.ymgme.2021.12.004_bb0240","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ymgme.2021.12.004_bb0245","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2021.12.004_bb0250","first-page":"1","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2021.12.004_bb0255","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.ymgme.2021.12.004_bb0260","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.ymgme.2021.12.004_bb0265","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"23","key":"10.1016\/j.ymgme.2021.12.004_bb0270","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1136\/heartjnl-2020-317922","article-title":"Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease","volume":"107","author":"El Sayed","year":"2021","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.ymgme.2021.12.004_bb0275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jimd.12176","article-title":"Neutralizing anti-drug antibodies in fabry disease can inhibit endothelial enzyme uptake and activity","volume":"43","author":"Stappers","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2021.12.004_bb0280","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase a in Fabry disease: subclass analysis and impact on response to treatment","volume":"126","author":"van der Veen","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2021.12.004_bb0285","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"issue":"8 Pt 2","key":"10.1016\/j.ymgme.2021.12.004_bb0290","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc. Imaging"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221011896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221011896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:52:08Z","timestamp":1761090728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221011896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1096719221011896"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.12.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}